Abstract
p-Methoxymethamphetamine (PMMA) is a new designer drug, listed in many countries as a controlled substance. Several fatalities have been attributed to the abuse of this designer drug. Previous in vivo studies using Wistar rats had shown that PMMA was metabolized mainly by O-demethylation. The aim of the study presented here was to identify the human hepatic cytochrome P450 (P450) enzymes involved in the biotransformation of PMMA to p-hydroxymethamphetamine. Baculovirus-infected insect cell microsomes, pooled human liver microsomes (pHLMs), and CYP2D6 poor-metabolizer genotype human liver microsomes (PM HLMs) were used for this purpose. Only CYP2D6 catalyzed O-demethylation. The apparent Km and Vmax values in baculovirus-infected insect cell microsomes were 4.6 ± 1.0 μM and 92.0 ± 3.7 pmol/min/pmol P450, respectively, and 42.0 ± 4.0 μM and 412.5 ± 10.8 pmol/min/mg protein in pHLMs. Inhibition studies with 1 μM quinidine showed significant inhibition of the metabolite formation (67.2 ± 0.6%; p < 0.0001), and comparison of the metabolite formation between pHLMs and PM HLMs revealed significantly lower metabolite formation in the incubations with PM HLMs (87.3 ± 1.1%; p < 0.0001). According to these studies, CYP2D6 is the major P450 involved in O-demethylation of PMMA.
Footnotes
-
↵1 Abbreviations used are: PMMA, p-methoxymethamphetamine, International Union of Pure and Applied Chemistry (IUPAC): [1-(4-methoxyphenyl)propane-2-yl](methyl)azane); MDMA, methylenedioxymethamphetamine, IUPAC: [1-(1,3-benzodioxol-5-yl)propane-2-yl](methyl)azane; HO-MA, p-hydroxymethamphetamine, IUPAC: [1-(4-hydroxyphenyl)propane-2-yl](methyl)azane; P450, cytochrome P450; pHLM, pooled human liver microsome; PM HLM, CYP2D6 poor-metabolizer genotype human liver microsome; HO-AM, p-hydroxyamphetamine, IUPAC: 1-(4-hydroxyphenyl)propane-2-ylazane); IS, internal standard; LC-MS, liquid chromatography-mass spectrometry; PM, CYP2D6 poor metabolizer; EM, CYP2D6 extensive metabolizer.
- Received October 30, 2003.
- Accepted January 13, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
